Company Description
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States.
It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.
It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body.
The company was founded in 2006 and is based in Framingham, Massachusetts.
| Country | MA |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Terrence W. Norchi M.D. |
Contact Details
Address: 235 Walnut Street, Suite 6 Framingham, Massachusetts 01702 United States | |
| Phone | 617-431-2313 |
| Website | archtherapeutics.com |
Stock Details
| Ticker Symbol | ARTH |
| Exchange | OTCMKTS |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001537561 |
| CUSIP Number | 03939W109 |
| ISIN Number | US03939W2089 |
| Employer ID | 46-0524102 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terrence W. Norchi M.D. | Co-Founder, Chairman, President and Chief Executive Officer |
| Michael S. Abrams | Chief Financial Officer and Treasurer |
| Dr. Rutledge Ellis-Behnke Ph.D. | Co-Founder and Scientific Advisor |
| Shawn Carlson | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2024 | 8-K | Current Report |
| Jul 5, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 18, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 3, 2024 | 8-K | Current Report |